arrow
P

Patrick Starlinger

Mayo Clinic
H指数:34
被引数:3,198

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Blood- and Liver Stiffness-Based Non-Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC

基于血液和肝脏硬度检测的无创性检查在慢性肝纤维化相关肝硬化及肝癌患者中临床显著门静脉高压的诊断应用

2026-10-280
OAAI
Predictors of morbidity and oncological benefit after liver resection with vascular reconstruction: international collaborative study from expert centres

肝脏血管重建术后并发症及肿瘤学获益的预测因素:多中心国际协作研究

2026-09-280
OAAI
Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

II期研究: futibatinib联合pembrolizumab治疗FGF19表达型晚期肝细胞癌患者的疗效观察

2026-08-250
OAAI
Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease

神经内分泌肿瘤肝转移合并类癌心脏病患者肝切除的预后

2026-08-190
PRE
ASO Visual Abstract: Carcinoid Syndrome Impacts Long-Term Outcomes After Hepatectomy for Small Bowel Neuroendocrine Tumor Liver Metastasis

ASO视觉摘要:类癌综合征影响小肠神经内分泌肿瘤肝转移行肝切除术后长期预后

2025-11-030
PRE
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study

一线阿替利珠单抗/贝伐珠单抗或度伐利尤单抗/特瑞普利单抗在晚期肝细胞癌中的应用:一项真实世界、多中心回顾性研究

2025-11-010
PRE
Carcinoid Syndrome Impacts Long-Term Outcomes After Hepatectomy for Small Bowel Neuroendocrine Tumor Liver Metastasis

类癌综合征影响小肠神经内分泌肿瘤肝转移行肝切除后的长期结局

2025-10-030
PRE
PNPLA3 polymorphism worsens chemotherapy associated liver injury and affects overall survival in colorectal cancer patients with liver metastasis undergoing hepatic resection

PNPLA3多态性会加重化疗相关性肝损伤,并影响接受肝切除术的肝转移性结直肠癌患者的总生存期。

2025-09-160
PREAI
ASO Visual Abstract: Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma

ASO 视觉摘要:可切除边缘性胆管癌的新辅助吉西他滨、顺铂和度伐利尤单抗的单中心真实世界经验

2025-09-090
PRE
ASO Visual Abstract: Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel in Borderline Resectable CCA: A Real-World Exploratory Analysis

ASO视觉摘要:新辅助吉西他滨、顺铂和 Nab-Paclitaxel治疗后,边界可切除CCA的切除转化:一项真实世界探索性分析

2025-08-280
PRE